114 related articles for article (PubMed ID: 15639727)
1. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.
Fennell DA; C Steele JP; Shamash J; Sheaff MT; Evans MT; Goonewardene TI; Nystrom ML; Gower NH; Rudd RM
Lung Cancer; 2005 Feb; 47(2):277-81. PubMed ID: 15639727
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
Stebbing J; Powles T; McPherson K; Shamash J; Wells P; Sheaff MT; Slater S; Rudd RM; Fennell D; Steele JP
Lung Cancer; 2009 Jan; 63(1):94-7. PubMed ID: 18486273
[TBL] [Abstract][Full Text] [Related]
3. Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
Porta C; Zimatore M; Bonomi L; Imarisio I; Paglino C; Sartore-Bianchi A; Mutti L
Lung Cancer; 2005 Jun; 48(3):429-34. PubMed ID: 15893013
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
Lena MD; Ramlau R; Hansen O; Lorusso V; Wagner L; Barni S; Cristovao MM; Huber R; Alberola V; Mitrovic M; Colin C; Gasmi J
Lung Cancer; 2005 Apr; 48(1):129-35. PubMed ID: 15777980
[TBL] [Abstract][Full Text] [Related]
5. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
6. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma.
Zimling ZG; Sørensen JB; Gerds TA; Bech C; Andersen CB; Santoni-Rugiu E
Cancer Chemother Pharmacol; 2012 Nov; 70(5):743-54. PubMed ID: 22960937
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of vinflunine in malignant pleural mesothelioma.
Talbot DC; Margery J; Dabouis G; Dark G; Taylor H; Boussemart H; Cadic V; Pinel MC; Rivière A; Ollivier L; Ruffié P
J Clin Oncol; 2007 Oct; 25(30):4751-6. PubMed ID: 17947722
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
Katirtzoglou N; Gkiozos I; Makrilia N; Tsaroucha E; Rapti A; Stratakos G; Fountzilas G; Syrigos KN
Clin Lung Cancer; 2010 Jan; 11(1):30-5. PubMed ID: 20085865
[TBL] [Abstract][Full Text] [Related]
9. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.
Jackman DM; Kindler HL; Yeap BY; Fidias P; Salgia R; Lucca J; Morse LK; Ostler PA; Johnson BE; Jänne PA
Cancer; 2008 Aug; 113(4):808-14. PubMed ID: 18543326
[TBL] [Abstract][Full Text] [Related]
11. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
Berghmans T; Lafitte JJ; Paesmans M; Stach B; Berchier MC; Wackenier P; Lecomte J; Collon T; Mommen P; Sculier JP;
Lung Cancer; 2005 Oct; 50(1):75-82. PubMed ID: 16005104
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer.
Delozier T; Guastalla JP; Yovine A; Levy C; Chollet P; Mousseau M; Delva R; Coeffic D; Vannetzel JM; Zazzi ES; Brienza S; Cvitkovic E
Anticancer Drugs; 2006 Oct; 17(9):1067-73. PubMed ID: 17001180
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
[TBL] [Abstract][Full Text] [Related]
14. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura.
Kasseyet S; Astoul P; Boutin C
Cancer; 1999 Apr; 85(8):1740-9. PubMed ID: 10223568
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer.
Guerrero A; Servitja S; Rodríguez-Lescure A; Calvo L; del Barco S; Quintanar MT; Juárez JI; Gayo J; Llombart A; Tusquets I
Anticancer Drugs; 2011 Mar; 22(3):283-9. PubMed ID: 21150776
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
van Meerbeeck JP; Gaafar R; Manegold C; Van Klaveren RJ; Van Marck EA; Vincent M; Legrand C; Bottomley A; Debruyne C; Giaccone G; ;
J Clin Oncol; 2005 Oct; 23(28):6881-9. PubMed ID: 16192580
[TBL] [Abstract][Full Text] [Related]
18. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
Fizazi K; Doubre H; Le Chevalier T; Riviere A; Viala J; Daniel C; Robert L; Barthélemy P; Fandi A; Ruffié P
J Clin Oncol; 2003 Jan; 21(2):349-54. PubMed ID: 12525529
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A
J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838
[TBL] [Abstract][Full Text] [Related]
20. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
